{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,22]],"date-time":"2026-02-22T04:54:21Z","timestamp":1771736061435,"version":"3.50.1"},"reference-count":27,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Emergency Medicine"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1016\/j.annemergmed.2014.07.014","type":"journal-article","created":{"date-parts":[[2014,8,30]],"date-time":"2014-08-30T16:27:48Z","timestamp":1409416068000},"page":"204-213","source":"Crossref","is-referenced-by-count":61,"title":["Ecallantide for the Acute Treatment of Angiotensin-Converting Enzyme Inhibitor\u2013Induced Angioedema: A Multicenter, Randomized, Controlled Trial"],"prefix":"10.1016","volume":"65","author":[{"given":"Lawrence M.","family":"Lewis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles","family":"Graffeo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pascal","family":"Crosley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Howard A.","family":"Klausner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carol L.","family":"Clark","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony","family":"Frank","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Miner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan","family":"Iarrobino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yung","family":"Chyung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.annemergmed.2014.07.014_bib1","doi-asserted-by":"crossref","first-page":"171","DOI":"10.2165\/00002018-199818030-00003","article-title":"ACE inhibitor-induced angioedema: incidence, prevention and management","volume":"18","author":"Vleeming","year":"1998","journal-title":"Drug Saf"},{"key":"10.1016\/j.annemergmed.2014.07.014_bib2","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.amjhyper.2003.09.014","article-title":"Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment versus Enalapril (OCTAVE) trial","volume":"17","author":"Kostis","year":"2004","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.annemergmed.2014.07.014_bib3","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S1081-1206(10)60594-7","article-title":"Multicenter study of patients with angiotensin-converting enzyme inhibitor-induced angioedema who present to the emergency department","volume":"100","author":"Banerji","year":"2008","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.annemergmed.2014.07.014_bib4","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/S1081-1206(10)60267-0","article-title":"Angiotensin-converting enzyme inhibitor-induced angioedema in a community hospital emergency department","volume":"103","author":"Bluestein","year":"2009","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.annemergmed.2014.07.014_bib5","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1001\/archinte.165.14.1637","article-title":"Incidence and characteristics of angioedema associated with enalapril","volume":"165","author":"Kostis","year":"2005","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.annemergmed.2014.07.014_bib6","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/j.1365-2753.2003.00484.x","article-title":"An evaluation of risk factors for adverse drug events associated with angiotensin-converting enzyme inhibitors","volume":"10","author":"Morimoto","year":"2004","journal-title":"J\u00a0Eval Clin Pract"},{"key":"10.1016\/j.annemergmed.2014.07.014_bib7","doi-asserted-by":"crossref","first-page":"88","DOI":"10.2500\/aap2008.29.3085","article-title":"Ten-year study of causes of moderate to severe angioedema seen by an inpatient allergy\/immunology consult service","volume":"29","author":"Banerji","year":"2008","journal-title":"Allergy Asthma Proc"},{"key":"10.1016\/j.annemergmed.2014.07.014_bib8","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S1567-5769(02)00162-5","article-title":"Bradykinin and the pathophysiology of angioedema","volume":"3","author":"Cugno","year":"2003","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.annemergmed.2014.07.014_bib9","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.iac.2006.08.001","article-title":"Angiotensin-converting enzyme inhibitor-associated angioedema","volume":"26","author":"Byrd","year":"2006","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.annemergmed.2014.07.014_bib10","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1067\/mai.2002.121316","article-title":"Pathways for bradykinin formation\u00a0and inflammatory disease","volume":"109","author":"Kaplan","year":"2002","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.annemergmed.2014.07.014_bib11","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1001\/jama.1988.03410070095035","article-title":"Clinical profile of angioedema associated with angiotensin-converting-enzyme inhibition","volume":"260","author":"Slater","year":"1988","journal-title":"JAMA"},{"key":"10.1016\/j.annemergmed.2014.07.014_bib12","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1503\/cmaj.060535","article-title":"Angioedema without urticaria: a large clinical survey","volume":"175","author":"Zingale","year":"2006","journal-title":"CMAJ"},{"key":"10.1016\/j.annemergmed.2014.07.014_bib13","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.jemermed.2013.03.045","article-title":"Angioedema: etiology, pathophysiology, current and emerging therapies","volume":"45","author":"Lewis","year":"2013","journal-title":"J\u00a0Emerg Med"},{"key":"10.1016\/j.annemergmed.2014.07.014_bib14","first-page":"333","article-title":"Consensus statement on the\u00a0diagnosis, management, and treatment of angioedema mediated by bradykinin, part I: classification, epidemiology, pathophysiology, genetics, clinical symptoms, and diagnosis","volume":"21","author":"Caballero","year":"2011","journal-title":"J\u00a0Investig Allergol Clin Immunol"},{"key":"10.1016\/j.annemergmed.2014.07.014_bib15","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1001\/archinte.164.8.910","article-title":"Angioedema associated with angiotensin-converting enzyme inhibitor use: outcome after switching to a different treatment","volume":"164","author":"Cicardi","year":"2004","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.annemergmed.2014.07.014_bib16","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1002\/lary.22349","article-title":"Management of angiotensin-converting enzyme inhibitor-induced angioedema","volume":"121","author":"Al-Khudari","year":"2011","journal-title":"Laryngoscope"},{"key":"10.1016\/j.annemergmed.2014.07.014_bib17","series-title":"Kalbitor [package insert]","year":"2012"},{"key":"10.1016\/j.annemergmed.2014.07.014_bib18","doi-asserted-by":"crossref","first-page":"859","DOI":"10.4155\/cli.13.76","article-title":"Ecallantide for the treatment of acute attacks of hereditary angioediema due to C1-inhibitor deficiency","volume":"3","author":"Bernstein","year":"2013","journal-title":"Clin Invest"},{"key":"10.1016\/j.annemergmed.2014.07.014_bib19","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0194-5998(99)70182-8","article-title":"Predicting airway risk in angioedema: staging system based on presentation","volume":"121","author":"Ishoo","year":"1999","journal-title":"Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.annemergmed.2014.07.014_bib20","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa0905079","article-title":"Ecallantide for the treatment of acute attacks in hereditary angioedema","volume":"363","author":"Cicardi","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annemergmed.2014.07.014_bib21","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.anai.2010.04.012","article-title":"EDEMA4: a phase 3, double-blind study of subcutaneous ecallantide treatment for acute attacks of hereditary angioedema","volume":"104","author":"Levy","year":"2010","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.annemergmed.2014.07.014_bib22","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jaci.2011.03.006","article-title":"Ecallantide (DX-88) for acute hereditary angioedema attacks: integrated analysis of 2 double-blind phase 3 studies","volume":"128","author":"Sheffer","year":"2011","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.annemergmed.2014.07.014_bib23","unstructured":"Code of Federal Regulations Title 21. 75 59961, September 29, 2010; last updated June 1, 2013."},{"key":"10.1016\/j.annemergmed.2014.07.014_bib24","unstructured":"ICH Statistical Principles for Clinical Trials. E9. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2009\/09\/WC500002928.pdf."},{"key":"10.1016\/j.annemergmed.2014.07.014_bib25","doi-asserted-by":"crossref","first-page":"267","DOI":"10.2500\/aap.2013.34.3664","article-title":"Factors associated with hospitalization of patients with angiotensin-converting enzyme inhibitor-induced angioedema","volume":"34","author":"Gang","year":"2013","journal-title":"Allergy Asthma Proc"},{"key":"10.1016\/j.annemergmed.2014.07.014_bib26","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2500\/aap.2013.34.3653","article-title":"Efficacy and safety of ecallantide in treatment of recurrent attacks of hereditary angioedema: open-label continuation study","volume":"34","author":"Lumry","year":"2013","journal-title":"Allergy Asthma Proc"},{"key":"10.1016\/j.annemergmed.2014.07.014_bib27","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1586\/eci.09.60","article-title":"Ecallantide: its pharmacology, pharmacokinetics, clinical efficacy and tolerability","volume":"6","author":"Bernstein","year":"2010","journal-title":"Expert Rev Clin Immunol"}],"container-title":["Annals of Emergency Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0196064414006210?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0196064414006210?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,30]],"date-time":"2018-09-30T01:24:58Z","timestamp":1538270698000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0196064414006210"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["S0196064414006210"],"URL":"https:\/\/doi.org\/10.1016\/j.annemergmed.2014.07.014","relation":{},"ISSN":["0196-0644"],"issn-type":[{"value":"0196-0644","type":"print"}],"subject":[],"published":{"date-parts":[[2015,2]]}}}